The letter comes after FDA inspections conducted in mid-2024 and late 2024, citing deficiencies in the company’s responses to previous observations, according to a Securities and Exchange Commission filing.
Despite the warning letter, Dexcom said in the filing it does not anticipate a material impact on manufacturing capacity or 2025 revenue.
The FDA notice does not limit the company’s ability to manufacture, market or distribute products, the filing said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.